Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer

por Chen, Kenneth, Kostos, Louise, Azad, Arun A.
Publicado 2022

Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer

por Kostos, Louise, Buteau, James P., Hofman, Michael S., Azad, Arun A.
Publicado 2023

Modern paradigms for prostate cancer detection and management

por Williams, Isabella SC, McVey, Aoife, Perera, Sachin, O’Brien, Jonathan S, Kostos, Louise, Chen, Kenneth, Siva, Shankar, Azad, Arun A, Murphy, Declan G, Kasivisvanathan, Veeru, Lawrentschuk, Nathan, Frydenberg, Mark
Publicado 2022

AlphaBet: Combination of Radium-223 and [(17)(7)Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)

por Kostos, Louise, Buteau, James P., Yeung, Theresa, Iulio, Juliana Di, Xie, Jing, Cardin, Anthony, Chin, Kwang Y., Emmerson, Brittany, Owen, Katie L., Parker, Belinda S., Fettke, Heidi, Furic, Luc, Azad, Arun A., Hofman, Michael S.
Publicado 2022

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype

por Fettke, Heidi, Dai, Chao, Kwan, Edmond M., Zheng, Tiantian, Du, Pan, Ng, Nicole, Bukczynska, Patricia, Docanto, Maria, Kostos, Louise, Foroughi, Siavash, Brown, Stephen, Graham, Lisa-Jane K., Mahon, Kate, Horvath, Lisa G., Jia, Shidong, Kohli, Manish, Azad, Arun A.
Publicado 2023